Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024

IMMUNIC, INC.

2023-Q2 EPS reported -$1.12

Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.
Cash, cash equivalents and investments at $77.3M as of June 30, 2023.
R&D expenses $21.2M, up from $16.5M YoY, driven by MS and IMU-856 programs.
Interim CALLIPER trial data in progressive MS expected fall 2023; ENSURE top-line late 2024.
Positive Phase 1b IMU-856 data in celiac disease; Phase 2 in active celiac being prepared.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUNIC, INC. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Immunic, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-23-001054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.